Companion Diagnostic Testing Market by Indication or Disease Type (Breast Cancer, Colorectal Cancer, Gastric Cancer, Lung Cancer, Melanoma) and Forecast 2017-2021

Companion Diagnostic Testing Market by Indication or Disease Type (Breast Cancer, Colorectal Cancer, Gastric Cancer, Lung Cancer, Melanoma) and Forecast 2017-2021

The emergence of targeted therapies in oncology brings an increased need for companion diagnostic tests. Companion diagnostics are medical devices that help physicians to decide the treatments and effective dosage for patients and which are tailored specifically to the patient. It is an in vitro device, which provides information that is essential for the safe and effective use of a corresponding drug or biological product. Companion diagnostics (CDx) are the molecular tests or assays intended to assist physicians in making effective treatment decisions based on the patient response to the ongoing treatment with targeted therapeutic medicines. These diagnostic tests ensure the commercialization of safer and efficient targeted therapeutics with minimal or no side effects, while ensuring economic benefits to the patients.

The global companion diagnostic testing market report estimates the market size (Revenue USD million – 2014 to 2021) for market segmentation based on indication or disease type (breast cancer, colorectal cancer, gastric cancer, lung cancer, melanoma, etc.), and forecasts growth trends (CAGR% – 2017 to 2021).

The global companion diagnostic testing market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global companion diagnostic testing market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

Major players operating in the global companion diagnostic testing market and included in this report are Roche Holdings AG, Abbott Laboratories, Genomic Health, Inc., Qiagen N.V., Life Technologies Corporation, Agilent Technologies, Inc. and GE Healthcare, Ltd.

  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue USD Million, 2014-2021)
    • Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Products
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Diagnostic Test Type
    • Indication or Infection Type
    • Technology
    • Diagnostics Application
    • Service Type
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • Device Classification I, II, III, IV
    • Device (FDA, EMEA) Approvals
  8. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  9. Recommendations
  10. References

Companion Diagnostics Market

1. Indication (Cancer Type))
1.1. Breast Cancer
1.2. Colorectal Cancer
1.3. Gastric Cancer
1.4. Lung Cancer
1.5. Melanoma
1.6. Others (HIV, Thalassemia)

2. Company Profiles
2.1. Abbott Laboratories
2.2. Agendia N.V.
2.3. Agilent Technologies, Inc.
2.4. BioGenex Laboratories Inc.
2.5. bioMérieux SA
2.6. GE Healthcare
2.7. Genomic Health, Inc.
2.8. F. Hoffmann-La Roche Ltd.
2.9. Qiagen N.V.
2.10. Resonance Health Analysis Services Pty Ltd.
2.11. Siemens Healthcare
2.12. Thermo Fisher Scientific (Life Technologies Corp.)

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*